Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Items 301–400 of 1,000
Mori, T., Ikeda, D. D., Yamaguchi, Y., & Unoki, M. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.038 · Cited by 52
“The G1 cyclins (D and E) are important in the G1/S transition, where they determine whether a cell enters another round of cell division [37,42,43].”
BackgroundLou, X., Zhang, J., Liu, S., Lou, X., & Liao, D. J. (2014) · Cell Cycle · doi:10.4161/cc.29082 · Cited by 51
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.
Augello, M. A., Burd, C., Birbe, R., McNair, C., Ertel, A., Magee, M., Frigo, D., Wilder-Romans, K., Shilkrut, M., Han, S.-M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64750 · Cited by 49
“These unbiased analyses are consistent with previous findings that demonstrated that cyclin D1a associates with and modulates activity of both estrogen receptor α (ER α ) (2, 13, 14) and the androgen receptor (AR) (2, 15–18) in breast and prostate cancer (PCa) cells, respectively.”
Kikkawa, N., Kinoshita, T., Nohata, N., Hanazawa, T., Yamamoto, N., FUKUMOTO, I., Chiyomaru, T., Enokida, H., Nakagawa, M., Okamoto, Y., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2349 · Cited by 50
Ginger extract adjuvant to doxorubicin in mammary carcinoma: study of some molecular mechanisms
El‐Ashmawy, N. E., Khedr, N. F., El‐Bahrawy, H. A., & Mansour, H. E. A. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1382-6 · Cited by 50
Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells
Body, S., Esteve‐Arenys, A., Miloudi, H., Recasens-Zorzo, C., Tchakarska, G., Moros, A., Bustany, S., Vidal‐Crespo, A., Rodríguez, V., Lavigne, R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14222-1 · Cited by 50
He, Z., Dang, J., Song, A., Cui, X., Ma, Z., & Zhang, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28557 · Cited by 54
Migliaccio, I., Bonechi, M., McCartney, A., Guarducci, C., Benelli, M., Biganzoli, L., Leo, A. D., & Malorni, L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102136 · Cited by 59
An update on the implications of cyclin D1 in melanomas
González‐Ruiz, L., González‐Moles, M. Á., González‐Ruiz, I., Ruiz‐Ávila, I., Ayén, Á., & Ramos‐García, P. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12874 · Cited by 49
“The use of mTOR inhibitors has been proposed to target CD1 because the translocation of CCND1 mRNA is mTOR-dependent (Musgrove et al., 2011).”
BackgroundCyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
Susanti, N. M. P., & Tjahjono, D. H. (2021) · Molecules · doi:10.3390/molecules26154462 · Cited by 54
“In addition, phosphorylated CDKN1B protein, a member of CIP/KIPs, allosterically activates the CDK4-cyclin D1 complex and induces structural changes forming the active conformation for catalysis.”
BackgroundInfluentialKassem, A. F., Omar, M. A., Nossier, E. S., Awad, H. M., & El‐Sayed, W. A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136358 · Cited by 49
Silvan, S., & Manoharan, S. (2012) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2012.06.005 · Cited by 49
MPHOSPH1: A Potential Therapeutic Target for Hepatocellular Carcinoma
Liu, X., Zhou, Y., Liu, X., Peng, A., Gong, H., Huang, L., Ji, K., Petersen, R. B., Zheng, L., & Huang, K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1279 · Cited by 49
“Expression of the G1 phase cyclin-D1, a critical oncoprotein in several cancers as the driver for entering the cell cycle (16), was significantly reduced by the downregulation of MPHOSPH1 (Fig.”
BackgroundLi, M., Tian, L., Ren, H. J., Chen, X., Wang, Y., Ge, J., Wu, S., Sun, Y.-N., Liu, M., & Xiao, H. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0626-6 · Cited by 53
Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model
Zhu, X., Enomoto, K., Zhao, L., Zhu, Y. J., Willingham, M. C., Meltzer, P. S., Qi, J., & Cheng, S.-Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0914 · Cited by 54
“Cyclin D1 is a critical regulator in cell-cycle progression and its deregulation is frequent in cancer (39).”
BackgroundGyanchandani, R., Kota, K. J., Jonnalagadda, A. R., Minteer, T., Knapick, B. A., Oesterreich, S., Brufsky, A., Lee, A. V., & Puhalla, S. L. (2016) · Oncotarget · doi:10.18632/oncotarget.11383 · Cited by 50
“Cyclin D1 and cyclin-dependent kinase 4/6 (CDK4/6) complex pathway regulates cell cycle progression from G1-phase to S-phase by phosphorylation and inactivation of the retinoblastoma protein (Rb) [16].”
BackgroundHuang, J., Zheng, C., Shao, J., Chen, L., Liu, X., & Shao, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.116 · Cited by 49
Cytotoxic Effects of Fascaplysin against Small Cell Lung Cancer Cell Lines
Hamilton, G. (2014) · Marine Drugs · doi:10.3390/md12031377 · Cited by 49
“Both CDK4 and CDK6 encode cyclin-dependent serine-threonine kinases that, complex with D-type cyclines to phosphorylate the RB tumor suppressor protein, in turn resulting in transcription of genes required for G1-S phase cell cycle progression [22].”
BackgroundMangini, N. S., Wesolowski, R., Ramaswamy, B., Lustberg, M. B., & Berger, M. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015602273 · Cited by 55
Cortés, J., Im, S., Holgado, E., Pérez-García, J. M., Schmid, P., & Chávez‐MacGregor, M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.011 · Cited by 52
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 55
“Thus, cyclin D1 may be indirectly targeted by compounds that lead to reduced expression of CCND1 or inhibit its primary binding partner CDK4/6 [173].”
BackgroundNFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation
Bera, A., Ghosh‐Choudhury, N., Dey, N., Das, F., Kasinath, B. S., Abboud, H. E., & Choudhury, G. G. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.005 · Cited by 48
Chemopreventive Effects of Licorice and Its Components
Bode, A. M., & Dong, Z. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-014-0015-5 · Cited by 51
“Overexpression of the cyclin D1 gene and protein plays an important role in fueling carcinogenesis [78] .”
BackgroundZamir‐Nasta, T., Razi, M., Hasanzadeh, S., & Malekinejad, H. (2017) · Environmental Toxicology · doi:10.1002/tox.22524 · Cited by 51
Wang, Y., Mang, X., Li, D., Chen, Y., Cai, Z., & Tan, F. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.07.036 · Cited by 49
Epigenetically altered miR‐193b targets cyclin D1 in prostate cancer
Kaukoniemi, K. M., Rauhala, H. E., Scaravilli, M., Latonen, L., Annala, M., Vessella, R. L., Nykter, M., Tammela, T. L. J., & Visakorpi, T. (2015) · Cancer Medicine · doi:10.1002/cam4.486 · Cited by 47
“In addition to its catalytic function, cyclin D1 also has noncatalytic functions, with the major function being transcriptional regulation [17].”
BackgroundZhou, X., Zeng, X., Tian, D., Xu, H., Cai, Q., Wang, J., & Chen, Q. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.047 · Cited by 47
“Growing evidence demonstrated that CCND1 is a potential therapeutic target in cancer [26,27].”
BackgroundGremel, G., Liew-Littorin, M., Hamzei, F., Hardell, E., Selling, J., Ghaderi, M., Stemme, S., Pontén, F., & Carlson, J. W. (2014) · International Journal of Cancer · doi:10.1002/ijc.29141 · Cited by 47
“Another possible treatment target are CDK4 and CDK6, two kinases associated with cyclin D1, which is overexpressed in YWHAE-FAM22 sarcomas.(41,42) The mechanism underlying this overexpression in these sarcomas is unknown.”
BackgroundGenetic variations in colorectal cancer risk and clinical outcome
Zhang, K., Civan, J., Mukherjee, S., Patel, F., & Yang, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4167 · Cited by 59
Venkatesan, S., Lamfers, M. L. M., Dirven, C. M. F., & Leenstra, S. (2016) · CNS Oncology · doi:10.2217/cns-2015-0005 · Cited by 53
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 52
Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors
Sharma, P., Alsharif, S., Bursch, K. L., Parvathaneni, S., Anastasakis, D. G., Chahine, J. J., Fallatah, A., Nicolas, K., Sharma, S., Hafner, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51195-9 · Cited by 48
Zhang, X., Min, K., Wimalasena, J., & Baek, S. J. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1276-1 · Cited by 48
“demonstrated to be aberrantly overexpressed in cancer cells or tumor (Musgrove et al. 2011).”
InfluentialD-Type Cyclins in Development and Disease
Saleban, M., Harris, E. L., & Poulter, J. A. (2023) · Genes · doi:10.3390/genes14071445 · Cited by 53
Zhao, Y., Yu, D., Li, H., Nie, P., Zhu, Y. K., Liu, S., Zhu, M., & Fang, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093210 · Cited by 46
“These procedures will also in turn lead to the transcriptional activation of E2F-responsive genes that are essential to cyclin E and cyclin A synthesis, therefore further promote the phosphorylation of Rb through activating CDK2 [12].”
BackgroundHan, Y., Xia, G., & Tsang, B. K. (2013) · Biology of Reproduction · doi:10.1095/biolreprod.112.105106 · Cited by 47
“They act by binding to cyclin-dependent kinases and increase retinoblastoma protein phosphorylation and relieve inhibition of the transcription factor E2F [12,13].”
BackgroundZhang, J., Sun, J., Li, C., Qiao, H., & Hussain, Z. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01854-x · Cited by 47
Zhou, X., Qiu, W., Sathirapongsasuti, J. F., Cho, M. H., Mancini, J. D., Lao, T., Thibault, D. M., Litonjua, A. A., Bakke, P. S., Gulsvik, A., et al. (2013) · Genomics · doi:10.1016/j.ygeno.2013.02.010 · Cited by 48
“In contrast, BTG2, the only anti-proliferation gene included here [28], demonstrated significantly increased expression up to ~5 fold in HHIP shRNA-infected cells.”
BackgroundCryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling
Li, S., Wang, H., Liu, H., Liu, W., Huang, F., Wang, J., Wang, P., Zhang, X., & Zhou, J. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.962960 · Cited by 45
Quercetin reduces cyclin D1 activity and induces G1 phase arrest in HepG2 cells
Zhou, J., Li, L., FANG, L., Xie, H., Yao, W., Zhou, X., Xiong, Z., Wang, L., Li, Z., & Luo, F. (2016) · Oncology Letters · doi:10.3892/ol.2016.4639 · Cited by 45
“These proteins share a cyclin box and PEST sequence, but bind to different chromosomes (10).”
Lee, H. J., Lee, W. K., Kang, C. W., Ku, C. R., Cho, Y. H., & Lee, E. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.037 · Cited by 46
“This phosphorylation induces conformational change of RB, activating E2F transcription factors and thus enables E2F to transcribe the genes that are required for G1-S phase cell cycle progression and ultimately cell proliferation [10, 14, 15, 16].”
BackgroundTargeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3–NANOG Axis
Oh, S. J., Cho, H., Kim, S., Noh, K. H., Song, K., Lee, H.-J., Woo, S. R., Kim, S., Choi, C. H., Chung, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2325 · Cited by 46
“prognosis of oral, and head and neck squamous cell carcinomas after radiotherapy or chemo-radiotherapy (18).”
BackgroundInfluentialWang, H., Yao, H., Yi, B., Kazama, K., Liu, Y., Deshpande, D. A., Zhang, J., & Sun, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26930 · Cited by 45
“As cyclin D1 mutation and amplification are frequently observed in various tumors (Musgrove et al., 2011; Palmero & Peters, 1996) and dysregulation of both cyclin D1 and miR‐638 may contribute to tumorigenesis, identification of cyclin D1 as a direct target of miR‐638 may help us understand the…”
BackgroundGul, A., Leyland-Jones, B., Dey, N., & De, P. K. (2018) · Europe PMC (PubMed Central) · Cited by 48
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Gomatou, G., Trontzas, I. P., Ioannou, S., Drizou, M., Syrigos, N. K., & Kotteas, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06100-3 · Cited by 47
Elsayed, G. H., Dacrory, S., & Fahim, A. M. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.10.083 · Cited by 47
Bustany, S., Cahu, J., Guardiola, P., & Sola, B. (2015) · BMC Cancer · doi:10.1186/s12885-015-1240-y · Cited by 44
“Moreover, cyclin D1 is overexpressed in human cancers, including malignant hemopathies, after genetic alterations, such as chromosomal translocation, but also in the absence of any detectable genetic alteration [2].”
BackgroundSophia, J., Tanagala, K. K. K., Jaganathan, K., Mishra, R., & Nagini, S. (2016) · Scientific Reports · doi:10.1038/srep22192 · Cited by 44
Cell Cycle-independent Role of Cyclin D3 in Host Restriction of Influenza Virus Infection
Fan, Y., Mok, C. K. P., Chan, M. C. W., Zhang, Y., Nal, B., Kien, F., Bruzzone, R., & Sanyal, S. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.776112 · Cited by 44
“The M2-binding domain on cyclin D3 is largely outside of its cyclin box, which is responsible for binding to and activation of cyclindependent kinases (33, 34) and also the region in which the greatest homology occurs among the D-type cyclins (35).”
BackgroundCheng, R., Liu, Y.-J., Cui, J., Yang, M., Liu, X., Li, P., Wang, Z., Zhu, L., Lu, S., Zou, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16325 · Cited by 46
“Drugs that target this axis can be used in the treatment of cancers especially breast cancer [17, 18, 44, 45].”
BackgroundTranscriptional repression by androgen receptor: roles in castration-resistant prostate cancer
Yu, J., Gritsina, G., & Gao, W. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_19_19 · Cited by 48
Feng, W. W., & Kurokawa, M. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.100 · Cited by 49
“Moreover, Cyclin D1 (but not D2 or D3) has been shown to directly interact with ER to promote its transcriptional activity, thereby further establishing Cyclin D1 dependency in hormone receptor positive breast cancer[63].”
BackgroundTargeting key transcriptional factor STAT3 in colorectal cancer
Chalikonda, G., Lee, H., Aliya, S., & Huh, Y. S. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04156-8 · Cited by 44
“CCND2, one of the three D- type cyclin family members, regulates cell cycle (mainly G1-S phase transition), cell differentiation, and oncogenic transformation [30] when triggered by RT.”
BackgroundZeng, Y., Xiao, J., Xu, Y., Fan, W., Tian, L., Gao, Y., Chen, Y., & Hu, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00828 · Cited by 44
BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4
Morita, K., Masamoto, Y., Kataoka, K., Koya, J., Kagoya, Y., Yashiroda, H., Sato, T., Murata, S., & Kurokawa, M. (2015) · Leukemia · doi:10.1038/leu.2015.137 · Cited by 47
Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner
Qin, A., Yu, Q., Gao, Y., Tan, J., Huang, H., Qiao, Z., & Qian, W. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.048 · Cited by 43
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
Davidson, B., Abeler, V. M., Hellesylt, E., Holth, A., Shih, I., Skeie-Jensen, T., Chen, L., Yang, Y., & Wang, T. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.021 · Cited by 47
“Cyclin D1 is an established oncogene which has been shown to be deregulated in multiple cancers, and drugs targeting cyclin D are currently evaluated in clinical trials [24].”
BackgroundFilho, M. I. D. S., Försti, A., Weinhold, N., Meziane, I., Campo, C., Huhn, S., Nickel, J., Hoffmann, P., Nöthen, M. M., Jöckel, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.387 · Cited by 45
Hosseini, S., Chamani, J., Hadipanah, M. R., Ebadpour, N., Razgi, A. S. H., Mohammadzadeh, M., & Rahimi, H. R. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s195800 · Cited by 55
“One of the main etiologies of breast cancer is cyclin D overexpression, which causes cells to initiate the G1 phase of the cell cycle and activate the proliferation of signaling pathways .(5,6) Studies have reported an association between cyclinD1 overexpression and tumor growth.”
BackgroundConcomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics
Kato, S., Adashek, J. J., Shaya, J. A., Okamura, R., Jimenez, R. E., Lee, S., Sicklick, J. K., & Kurzrock, R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3761 · Cited by 44
“org Clin Cancer Res; 27(10) May 15, 2021 2795”
BackgroundInfluentialMiR ‐205‐5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer
Zhao, Y., Zhang, J. R., Yang, J., Wei, Y., Peng, J., Fu, C., Huang, M., Wang, R., Wang, P., Sun, G., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14331 · Cited by 50
“In addition, p53 could further regulate cyclin D1,(20) which activated CDK4/CDK6 to influence cell cycle by RB1.(21) Thus, the RB1, P21, and cyclin D1 levels in miR-205-5p-treated lung cancer cells were analyzed in the present study, and the results showed that miR-205-5p could decrease the expression of TP53INP1, RB1…”
BackgroundInfluentialAttractor landscape analysis of colorectal tumorigenesis and its reversion
Cho, S., Park, S., Lee, H.-S., Lee, H.-Y., & Cho, K. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0341-9 · Cited by 46
“The overexpression of CyclinD is known to cause a number of potentially oncogenic responses and many different types of cancer commonly have CyclinD overexpression rates of 15 ~ 40 % [34].”
BackgroundMunoz, I. M., Macartney, T., Sánchez‐Pulido, L., Ponting, C. P., Rocha, S., & Rouse, J. W. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382499 · Cited by 42
Alinari, L., Prince, C. J., Edwards, R. B., Towns, W. H., Mani, R., Lehman, A., Zhang, X., Jarjoura, D. G., Pan, L., Kinghorn, A. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0839 · Cited by 48
“The primary factors in the D-cyclin/CDK/E2F pathway have been reported to participate in cellular processes as diverse as DNA damage response and repair, differentiation, and apoptosis, in addition to cell-cycle control (2, 3, 46).”
Costa, R. L. B., Carneiro, B. A., Wainwright, D. A., Santa-Maria, C. A., Kumthekar, P., Chae, Y. K., Gradishar, W. J., Cristofanilli, M., & Giles, F. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw532 · Cited by 44
ETS‐targeted therapy: can it substitute for MEK inhibitors?
Tetsu, O., & McCormick, F. P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0147-4 · Cited by 45
“Thus, tumors that do not depend on CDK4/6 for G1-S transition and/ or can rescue CDK4/6 inhibition by the activity of other CDKs may require alternative approaches, including the use of compounds that affect cyclin D1 transcription or protein turnover and combination therapies that target multiple endpoints of cyclin…”
BackgroundKim, C., Terado, T., Tambe, Y., Mukaisho, K., Sugihara, H., Kawauchi, A., & Inoue, H. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4194 · Cited by 45
TNNT1 facilitates proliferation of breast cancer cells by promoting G1/S phase transition
Shi, Y., Zhao, Y., Zhang, Y., AiErken, N., Shao, N., Ye, R., Lin, Y., & Wang, S. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.034 · Cited by 42
Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
Stavrakaki, Ε., Dirven, C. M. F., & Lamfers, M. L. M. (2021) · Cancers · doi:10.3390/cancers13040614 · Cited by 47
“Over-expression of cyclin D1 has been observed in many cancer types like head and neck squamous cell carcinomas (HNSCC), pancreatic and breast cancer [114].”
BackgroundRepositioning of Antiparasitic Drugs for Tumor Treatment
Li, Y., Zheng, Z., Liu, Q., Lu, X., Zhou, D., Zhang, J., Zheng, H., & Dai, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670804 · Cited by 49
“More specifically, CDK4 encodes a cyclindependent serine-threonine kinase in response to mitogenic or proliferation-promoting stimuli and interacts with cyclin D1 to phosphorylate the tumor suppressor protein Rb (109, 110).”
BackgroundDNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC
Wang, Y., Ju, L., Wang, G., Qian, K., Jin, W., Li, M., Yu, J., Shi, Y., Wang, Y., Zhang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38160-x · Cited by 43
Roles of Cell Cyle Regulators Cyclin D1, CDK4, and p53 in Knee Osteoarthritis
Zhu, X., Yang, S., Lin, W., Wang, L., Ying, J., Ding, Y., & Chen, X. (2016) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2016.0020 · Cited by 42
“Cyclin D1 in cells entering the cell cycle is induced by extracellular signals and subsequently binds to and activates CDK4 (Musgrove et al. , 2011).”
Zhu, Y., Wen, X., & Zhao, P. (2018) · Medical Science Monitor · doi:10.12659/msm.909633 · Cited by 45
“CCND1 is a well-established human oncogene [14], which is commonly overexpressed in different types of cancers such as breast cancer [15], lung cancer [16], and melanoma [17].”
BackgroundLin, Z., Zhang, X., Zhao, F., & Ru, S. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.01.017 · Cited by 50
Targetable Pathways in the Treatment of Retroperitoneal Liposarcoma
Casadei, L., de Faria, F. C. C., Lopez‐Aguiar, A. G., Pollock, R. E., & Grignol, V. P. (2022) · Cancers · doi:10.3390/cancers14061362 · Cited by 44
“CDK4 is a cyclin-dependent kinases (CDK) that forms a complex with D-type Cyclins (CCND), thus playing an important role in cell cycle progression from G1 to S phase by allowing E2F to be released from pRb control [45].”
BackgroundZhang, D., Zhuang, Y., Pan, J.-C., Wang, H., Li, H., Yu, Y., & Wang, D. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/209843 · Cited by 45
“Upon RB phosphorylation by CDK4/6, RB dissociates from E2F-DP1 heterodimer, leading to the inactivation of its suppressor effect on DNA synthesis and the subsequent progression of the cell into S phase from G1 [22].”
BackgroundChen, E. Y., Dobrinski, K. P., Brown, K. H., Clagg, R., Edelman, E. J., Ignatius, M. S., Chen, J. Y., Brockmann, J., Nielsen, G. P., Ramaswamy, S., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003727 · Cited by 43
“While cyclin D1 is frequently dysregulated in cancer and is a marker for disease progression [32], the involvement of cyclin D2 in cancer is not as well characterized.”
BackgroundGao, Y., Shen, J. K., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0316-x · Cited by 41
Grizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & Petrelli, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202965 · Cited by 41
“Next-generation CDK inhibitors were developed with greater selectivity towards isoforms 4 and 6, resulting in more effective and less toxic compounds.(23) To date, there are three CDK4/6 inhibitors available in clinical practice, palbociclib, ribociclib and abemaciclib, which are slightly different in pharmacokinetics…”
BackgroundmiR-20b-5p functions as tumor suppressor microRNA by targeting cyclinD1 in colon cancer
Yang, H., Lin, J., Jiang, J., Ji, J., Wang, C., & Zhang, J. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1829824 · Cited by 41
“The most known function of CCND1 is to activate CDK4 and CDK6 and promote cell proliferation [37].”
BackgroundChen, Y., & Gibson, S. B. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166265 · Cited by 40
Molecular mechanisms of thyroid cancer: A competing endogenous RNA (ceRNA) point of view
Yang, L., Khan, S., Li, L., ten Hagen, T. L. M., & Falahati, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112251 · Cited by 40
Janoštiak, R., Torres-Sanchez, A., Posas, F., & de Nadal, E. (2022) · Cancers · doi:10.3390/cancers14051265 · Cited by 42
Abu-Khalaf, M. M., Hodge, K. A., Hatzis, C., Baldelli, E., Gazzah, E. E., Valdes, F., Sikov, W. M., Mita, M. M., Denduluri, N., Murphy, R., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00360-5 · Cited by 50
Seçme, M., Mutlu, D., Elmas, L., & Arslan, Ş. (2023) · South African Journal of Botany · doi:10.1016/j.sajb.2023.03.046 · Cited by 40
Nagaria, T. S., Williams, J. L., Leduc, C., Squire, J. A., Greer, P. A., & Sangrar, W. (2013) · Neoplasia · doi:10.1593/neo.13804 · Cited by 41
“FPD Potentiates SFN Cytotoxicity in MDA-MB-468 and SKBR3 Cells We extended our analyses to MDA-MB-468, SKBR3, MCF-7, and T47D cells and focused efforts on FPD, which has undergone extensive testing in clinical trials [22,25,26].”
Cyclin alterations in diverse cancers: outcome and co-amplification network
Schwaederle, M. C., Daniels, G. A., Piccioni, D. E., Fanta, P. T., Schwab, R. B., Shimabukuro, K. A., Parker, B. A., & Kurzrock, R. (2014) · Oncotarget · doi:10.18632/oncotarget.2848 · Cited by 40
“Amplifications of cyclin genes are amongst the most common alterations in cancers, with cyclin D1 (CCND1) amplification rates ranging from 15–40% [1].”
BackgroundInfluentialXu, J. L., & Lin, D. I. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199688 · Cited by 42
“Alterations of cyclin D1 resulting in nuclear protein expression is thought to promote tumorigenesis in various types of cancers[1][2], often as a result of CCND1 gene amplification, such as in breast, lung, bladder carcinomas [3][4], or as a result of CCND1 translocation in mantle cell lymphoma…”
Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications
Pratap, S., & Scordino, T. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.11.008 · Cited by 42
Cyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells
Ramezani-Rad, P., Chen, C., Zhu, Z., & Rickert, R. C. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108403 · Cited by 40
“Furthermore, kinase-Ramezani-Rad independent roles of D-type cyclins highlight unique features among its members, including cyclin D1 regulating DNA repair through interaction with Rad51 (Jirawatnotai et al., 2011; Musgrove et al., 2011).”
Konstantinopoulos, P. A., Cheng, S., Supko, J. G., Polak, M. M., Wahner-Hendrickson, A. E., Ivy, S. P., Bowes, B., Sawyer, H., Basada, P., Hayes, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01664-8 · Cited by 40
“Loss of CDKN2A leads to activation of CDK4 and CDK6, which similarly phosphorylate RB leading to activation of E2F transcriptional activity and accelerated G1- >S phase transition [30, 34].”
BackgroundPerumal, E., Gunadharini, D. N., Senthilkumar, K., Banudevi, S., Arunkumar, R., Selvanesan, B. C., Sharmila, G., & Arunakaran, J. (2012) · Biomedicine & Preventive Nutrition · doi:10.1016/j.bionut.2011.12.008 · Cited by 39
Oricchio, E., Ciriello, G., Jiang, M., Boice, M., Schatz, J. H., Heguy, A., Viale, A. J., de Stanchina, E., Teruya‐Feldstein, J., Bouska, A. C., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132120 · Cited by 40
Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway
Ding, D., Huang, H., Jiang, W. I., Yu, W., Zhu, H., Liu, J., Saiyin, H., Wu, J., Huang, H., Jiang, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.230 · Cited by 39
DNA Methylation of Tumor Suppressor Protein-Coding and Non-Coding Genes in Multiple Myeloma
Wong, K. Y., & Chim, C. S. (2015) · Epigenomics · doi:10.2217/epi.15.57 · Cited by 42
Telomerase activates transcription of cyclin D1 gene through an interaction with NOL1
Hong, J., Lee, J. H., & Chung, I. K. (2016) · Journal of Cell Science · doi:10.1242/jcs.181040 · Cited by 41
Khan, M. I., Dębski, K. J., Dąbrowski, M., Czarnecka, A. M., & Szczylik, C. A. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00138.2016 · Cited by 42
TGFβ/Smad3 regulates proliferation and apoptosis through IRS-1 inhibition in colon cancer cells
Bailey, K. L., Agarwal, E., Chowdhury, S., Luo, J., Brattain, M. G., Black, J. D., & Wang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176096 · Cited by 39
Hsu, C.-L., Lui, K., Chi, L., Kuo, Y., Chao, Y., Yeh, C., Lee, L., Huang, Y., Lin, T., Huang, M.-Y., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0873-5 · Cited by 39
Invadopodia-mediated ECM degradation is enhanced in the G1 phase of the cell cycle
Bayarmagnai, B., Perrin, L., Pourfarhangi, K. E., Graña, X., Tüzel, E., & Gligorijevic, B. (2019) · Journal of Cell Science · doi:10.1242/jcs.227116 · Cited by 43
“CCND1 gene expression level remained stable throughout the cell cycle, consistent with the reports that CCND1 is amplified in breast cancers (Musgrove et al., 2011).”
Result
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.